Cancer
Malignant Anal Neoplasm
CI-CAN-00007989Explore in graph →
Top-level68 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007989Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06670495 | HPV Genotype Attribution and Disease Burden of Anal Cancer in China | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03260023 |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers |
| active not recruiting |
| Phase 1 / Phase 2 |
| 143 |
| TransgeneINDUSTRY |
| 3 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT05838391 | Adaptive Radiation in Anal Cancer | recruiting | N/A | 20 | Columbia UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07112690 | Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment | recruiting | N/A | 5 | Emory UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07296237 | Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer(DACG VI) | recruiting | — | 80 | Aarhus University HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06522256 | Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial(HPVsign) | recruiting | N/A | 100 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05040815 | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer(INSPIRE) | recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06207981 | Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD) | recruiting | Phase 3 | 310 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Sep 2, 2025 | clinicaltrials |
| NCT06366841 | Stigma and Psychological profilE in REctal-anal caNcer pAtients(SERENA) | recruiting | — | 148 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07059442 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA)(SANCA) | not yet recruiting | N/A | 1,000 | Karolinska InstitutetOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06630793 | IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer(IMPAC) | recruiting | N/A | 108 | Tata Memorial CentreOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT01937780 | Anal Cancer Radiotherapy Study(ANCARAD) | active not recruiting | — | 75 | Oslo University HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05939401 | A Study Regarding Tissue Response During and After Treatment for Anal Cancer(ANCABio) | recruiting | — | 400 | Sahlgrenska University HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06697964 | High Resolution Anuscopy Study | recruiting | — | 500 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06792604 | Host Genome Methylation: a Screening Tool in Anal Cancer Detection(AMethysT) | recruiting | N/A | 770 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06619743 | HPV Infection and Vaginal Microecology in Immunosuppressed Women | not yet recruiting | — | 10,000 | Lan ZhuOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT05572801 | NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer | recruiting | N/A | 400 | Aarhus University HospitalOTHER | 4 | Aug 14, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06327568 | Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04792892 | ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer(ANCAII) | recruiting | — | 600 | Sahlgrenska University HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT05438836 | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer(ROAR-A) | recruiting | — | 205 | Herlev HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05055635 | Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)(ReRad III) | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03792854 | Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)(LANACARE) | recruiting | — | 100 | Ludwig-Maximilians - University of MunichOTHER | 1 | Jan 3, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Feb 20, 2026source: clinicaltrials